new-recommended-broker-banner new-recommended-broker-banner

Aethlon Stock Surges 103% After First Patient Treated In HEMOPURIFIER Trial

Updated: 16 Dec 2020

Medical device technology company Aethlon Medical (NASDAQ: AEMD) shares are surging premarket on Wednesday after the company said the first patient has been treated in its first-in-human visibility Early Feasibility Study (EFS) evaluating HEMOPURIFIER.

The study is treating patients with recurrent cancer and/or metastatic squamous cell carcinoma, a type of cancer of the head and neck. Aethlon is evaluating “the HEMOPURIFIER for reducing cancer-associated exosomes prior to the administration of standard-of-care pembrolizumab (KEYTRUDA).”

The EFS is the device equivalent of a Phase 1 trial for drugs and is a single centre open-label trial in 10-12 subjects.

“The initiation of this first-in-human study addressing cancer-associated exosomes is a significant step towards evaluating the HEMOPURIFIER® for potentially improving the efficacy of KEYTRUDA® in head and neck cancer,” commented Charles J Fisher Jr, Aethlon’s CEO.

Aethlon shares are up 103% at the time of this publication, trading at $3.29 after closing Tuesday’s session at $1.62.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .